title: Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma.
abstract: BACKGROUND
  We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin's lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and affects neo-angiogenesis.
  
  
  RESULTS
  Plasma miR-92a values in NHL were extremely low (<5%), compared with healthy subjects (P<.0001), irrespective of lymphoma sub-type. The very low plasma level of miR-92a increased in the complete response (CR) phase but did not reach the normal range, and the plasma level was lower again in the relapse phase. Patients in CR or CR unconfirmed with a plasma miR-92a level of less than the cut-off level showed a significantly high relapse rate compared with patients with normalized plasma miR-92a level.
  
  
  CONCLUSIONS
  The current results therefore indicate that the plasma miR-92a value could be a novel biomarker not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.
authors.affiliation: Hematology Division, First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan. ohyashik@rr.iij4u.or.jp
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ohyashiki
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Umezu
authors.forename: Sei-Ichiro
authors.initials: S
authors.lastname: Yoshizawa
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Ito
authors.forename: Michiyo
authors.initials: M
authors.lastname: Ohyashiki
authors.forename: Hisashi
authors.initials: H
authors.lastname: Kawashima
authors.forename: Masami
authors.initials: M
authors.lastname: Tanaka
authors.forename: Masahiko
authors.initials: M
authors.lastname: Kuroda
authors.forename: Junko H
authors.initials: JH
authors.lastname: Ohyashiki
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000097:blood; D001774:Blood Chemical Analysis / Q000379:methods; D015536:Down-Regulation; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D035683:MicroRNAs / Q000032:analysis / Q000097:blood* / Q000235:genetics; D046228:Microarray Analysis; D008875:Middle Aged; D011379:Prognosis; D012306:Risk; D054928:Validation Studies as Topic
chemical_list: D014408:Biomarkers, Tumor; C541874:MIRN92 microRNA, human; D035683:MicroRNAs